文献速递产科妇科

完全性葡萄胎与正常胎儿共存的多胎妊娠:141例患者的回顾性队列研究

Multiple pregnancy with complete hydatidiform mole and coexisting normal fetus in a retrospective cohort of 141 patients.
PubMed 文献 · Am J Obstet Gynecol · 2023-09-16

该回顾性全国队列研究纳入141例组织学确诊的完全性葡萄胎与正常胎儿共存多胎妊娠,23%终止妊娠,继续妊娠者中8天新生儿存活率36%,妊娠滋养细胞肿瘤发生率26%且均为低危、治愈率100%,游离β-hCG<10 MoM与更可能达24周及更好早期新生儿存活相关。

要点

  • 完全性葡萄胎与正常胎儿共存多胎妊娠中,23%(33/141)因预后差或自愿终止妊娠。
  • 继续妊娠者中,8天新生儿存活率为36%(39/108;95%CI 27-46)。
  • 妊娠滋养细胞肿瘤发生率为26%(35/136;95%CI 19-34),均为低危且治愈率100%。

核心结论

  • 完全性葡萄胎与正常胎儿共存多胎妊娠产科并发症风险高,继续妊娠者约三分之一新生儿8天存活,约四分之一发生妊娠滋养细胞肿瘤。
  • 与单发完全性葡萄胎相比,恶性转化风险似乎更高。
  • 低水平游离β-hCG可能提示更好的早期新生儿存活,该关系需进一步研究。

研究设计与样本

  • 回顾性全国队列研究,纳入法国国家滋养细胞疾病中心2001年1月至2022年1月登记的11411例记录。
  • 其中141例为组织学确诊的完全性葡萄胎与正常胎儿共存多胎妊娠。

主要发现

  • 23%(33/141)因推测预后差或自愿终止妊娠;继续妊娠的77%(108/141)中,16%(17/108)因母体并发症终止,37%(40/108)在24周前自然流产。
  • 剩余47%(51/108)分娩者的中位分娩孕周为32周;排除选择性终止妊娠后,8天新生儿总存活率为36%(39/108;95%CI 27-46)。
  • 游离β-hCG<10 MoM者达24周妊娠的可能性显著高于>10 MoM者(OR 7.0;95%CI 1.3-36.5;P=.022)。
  • 8天新生儿存活者的中位游离β-hCG为9.4 MoM,死亡者为20.0 MoM(P=.02)。
  • 妊娠滋养细胞肿瘤总发生率为26%(35/136;95%CI 19-34),35例均为低危FIGO评分,治愈率100%。

关键数值与推荐

  • 游离β-hCG<10 MoM vs >10 MoM达24周妊娠的OR为7.0(95%CI 1.3-36.5;P=.022)。
  • 8天新生儿存活者中位游离β-hCG 9.4 MoM vs 死亡者20.0 MoM(P=.02)。
  • 妊娠滋养细胞肿瘤发生率26%(35/136;95%CI 19-34),均为低危FIGO评分,治愈率100%。
  • 患者要求终止妊娠与妊娠滋养细胞肿瘤风险降低无关;子痫前期、产后出血、高hCG水平或8天新生儿存活与妊娠滋养细胞肿瘤风险升高无关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出低水平游离β-hCG与更好早期新生儿存活的关系需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multiple pregnancy with a complete hydatidiform mole and a normal fetus is prone to severe obstetrical complications and malignant transformation after birth. Prognostic information is limited for this rare form of gestational trophoblastic disease. OBJECTIVE: This study aimed to determine obstetrical outcomes and the risk of gestational trophoblastic neoplasia in women with multiple pregnancy with complete hydatidiform mole and coexisting normal fetus, and to identify risk factors for poor obstetrical and oncological outcomes to improve patient information and management. STUDY DESIGN: This was a retrospective national cohort study of 11,411 records from the French National Center for Trophoblastic Disease registered between January 2001 and January 2022. RESULTS: Among 11,411 molar pregnancies, 141 involved histologically confirmed multiple pregnancy with complete hydatidiform mole and coexisting normal fetus. Roughly a quarter of women (23%; 33/141) decided to terminate pregnancy because of presumed poor prognosis or by choice. Among the 77% of women (108/141) who continued their pregnancy, 16% of pregnancies (17/108) were terminated because of maternal complications, and 37% (40/108) ended in spontaneous miscarriage before 24 weeks' gestation. The median gestational age at delivery in the remaining 47% of pregnancies (51/108) was 32 weeks. The overall neonatal survival rate at day 8 was 36% (39/108; 95% confidence interval, 27-46) after excluding elective pregnancy terminations. Patients with free beta human chorionic gonadotropin levels <10 multiples of the median were significantly more likely to reach 24 weeks' gestation compared with those with free beta human chorionic gonadotropin levels >10 multiples of the median (odds ratio, 7.0; 95% confidence interval, 1.3-36.5; P=.022). A lower free beta human chorionic gonadotropin level was also associated with better early neonatal survival (the median free beta human chorionic gonadotropin level was 9.4 multiples of the median in patients whose child was alive at day 8 vs 20.0 multiples of the median in those whose child was deceased; P=.02). The overall rate of gestational trophoblastic neoplasia after a multiple pregnancy with complete hydatidiform mole and a normal fetus was 26% (35/136; 95% confidence interval, 19-34). All 35 patients had low-risk International Federation of Gynecology and Obstetrics scores, and the cure rate was 100%. Termination of pregnancy on patient request was not associated with lower risk of gestational trophoblastic neoplasia. Maternal complications such as preeclampsia and postpartum hemorrhage were not associated with higher risk of gestational trophoblastic neoplasia, and neither were high human chorionic gonadotropin levels or newborn survival at day 8. CONCLUSION: Multiple pregnancy with complete hydatidiform mole and coexisting fetus carries a high risk of obstetrical complications. In patients who continued their pregnancy, approximately one-third of neonates were alive at day 8, and roughly 1 in 4 patients developed gestational trophoblastic neoplasia. Therefore, the risk of malignant transformation appears to be higher compared with singleton complete moles. Low levels of free beta human chorionic gonadotropin may be indicative of better early neonatal survival, and this relationship warrants further study.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Hajri T, Massoud M, Vergne M, et al. Multiple pregnancy with complete hydatidiform mole and coexisting normal fetus in a retrospective cohort of 141 patients. Am J Obstet Gynecol. 2023. PMID: 37722570. doi:10.1016/j.ajog.2023.09.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。